SSKN Strata Skin Sciences

STRATA Skin Sciences to Present at the Inaugural Gilmartin Group Emerging Growth Company Showcase

STRATA Skin Sciences to Present at the Inaugural Gilmartin Group Emerging Growth Company Showcase

HORSHAM, Pa., Aug. 22, 2022 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (NASDAQ: SSKN), a medical technology company dedicated to developing, commercializing and marketing innovative products for the treatment of dermatologic conditions, today announced the company will present at the upcoming Inaugural Gilmartin Group Emerging Growth Company Showcase, taking place virtually. Members of management are scheduled to present on Wednesday, August 31, 2022 at 3:30 PM ET.

Interested parties can access a live webcast of the presentation directly by following this . An archived webcast of the presentation will be available on the “Investors” section of STRATA Skin Sciences website at following the event.

Those parties interested in registering for the Inaugural Gilmartin Group Emerging Growth Company Showcase may do so by following this .

About STRATA Skin Sciences, Inc.

STRATA Skin Sciences is a medical technology company in dermatology dedicated to developing, commercializing and marketing innovative products for the in-office treatment of dermatologic conditions. Its products include the XTRAC®, XTRAC Momentum™ 1.0 and Pharos® excimer lasers, VTRAC® lamp systems, and TheraClear® treatment systems utilized in the treatment of psoriasis, vitiligo, acne and various other skin conditions.

The Company’s proprietary XTRAC® and XTRAC Momentum™ 1.0 excimer lasers deliver a highly targeted therapeutic beam of UVB light to treat psoriasis, vitiligo, eczema, atopic dermatitis and leukoderma, diseases which impact over 31 million patients in the United States alone. In addition, STRATA's TheraClear®X, utilizes FDA-Cleared technology to address the estimated $5.5 billion market opportunity for acne treatment with a non-invasive, highly effective, in-office procedure.

STRATA’s unique business model, in the U.S., leverages targeted Direct to Consumer (DTC) advertising to generate awareness and utilizes its in-house call center and insurance advocacy teams to increase volume for the Company’s partner dermatology clinics.

Investor Contact

Jack Droogan

203-585-4140



EN
22/08/2022

Underlying

SSKNStrata Skin Sciences

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Strata Skin Sciences

 PRESS RELEASE
Free
SSKN Strata Skin Sci...

STRATA Skin Sciences Confirms Nasdaq Delisting

STRATA Skin Sciences Confirms Nasdaq Delisting HORSHAM, Pa., Feb. 19, 2026 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (“STRATA” or the “Company”) (NASDAQ: SSKN), a medical technology company dedicated to developing, commercializing, and marketing innovative products for the treatment of dermatologic conditions, announces that a Form 25 has been filed today with the SEC to deregister its common stock under Section 12(b) of the Securities Exchange Act of 1934, as amended (“Exchange Act”), and confirms that trading of the Company’s common stock has been suspended from trading on The Nasd...

February 19, 2026 1 EN
 PRESS RELEASE
Free
SSKN Strata Skin Sci...

Johns Hopkins Dermatology Expands Advanced Care for Inflammatory and A...

Johns Hopkins Dermatology Expands Advanced Care for Inflammatory and Autoimmune Skin Conditions with Addition of XTRAC® Excimer Laser Latest STRATA customer strengthens academic leadership in XTRAC excimer laser treatment for psoriasis, vitiligo, and atopic dermatitis HORSHAM, Pa., Feb. 18, 2026 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (Nasdaq: SSKN), a medical technology company dedicated to developing, commercializing, and marketing innovative dermatologic treatments, today announces that Johns Hopkins Dermatology has added the XTRAC® 308 nm excimer laser to its clinical treatme...

February 18, 2026 1 EN
 PRESS RELEASE
Free
SSKN Strata Skin Sci...

STRATA Skin Sciences Highlights Meta-Analysis Confirming Clinical Effi...

STRATA Skin Sciences Highlights Meta-Analysis Confirming Clinical Efficacy of 308 nm Excimer Laser for Plaque Psoriasis Growing body of clinical data like February 2026 publication from Georgetown University supports optimized, targeted Excimer laser UVB strategies for inflammatory skin conditions HORSHAM, Pa., Feb. 17, 2026 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (NASDAQ: SSKN), a medical technology company dedicated to developing, commercializing, and marketing innovative dermatologic treatments, today highlights findings from a February 2026 systematic review and meta-analysis...

February 17, 2026 1 EN
 PRESS RELEASE
Free
SSKN Strata Skin Sci...

STRATA Skin Sciences Showcases XTRAC® and TheraclearX® at TeraCILAD 20...

STRATA Skin Sciences Showcases XTRAC® and TheraclearX® at TeraCILAD 2025 — Reports Early Adoption Momentum in Mexico HORSHAM, Pa., Dec. 09, 2025 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (NASDAQ: SSKN), a global leader in in-office dermatologic technologies, announces its participation in the 2025 Ibero-Latin American Congress of Dermatology (TeraCILAD) November 19-22, 2025, where it presented its XTRAC® excimer laser and TheraclearX® acne therapy system. STRATA also reported that, by the end of 2025, there will be over 12 new recurring TheraclearX® accounts in Mexico, reflecting gro...

December 9, 2025 1 EN
Free Trial
SSKN Strata Skin Sci...

Strata Skin Sciences Inc: 1 director

A director at Strata Skin Sciences Inc sold/bought 19,094 shares at 1.334USD and the significance rating of the trade was 67/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last tw...

SSKN STRATA SKIN SCIENCES
11/19/25 November 19, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch